Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model.

Yang J, Pattanayak A, Song M, Kou J, Taguchi H, Paul S, Ponnazhagan S, Lalonde R, Fukuchi K.

J Mol Neurosci. 2013 Feb;49(2):277-88. doi: 10.1007/s12031-012-9877-3. Epub 2012 Sep 4.

2.

Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Deane R, Bell RD, Sagare A, Zlokovic BV.

CNS Neurol Disord Drug Targets. 2009 Mar;8(1):16-30. Review.

3.

Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease.

Chauhan NB, Siegel GJ.

Expert Rev Vaccines. 2004 Dec;3(6):717-25. Review.

PMID:
15606357
4.

Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans.

Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ.

Rejuvenation Res. 2006 Spring;9(1):77-84. Review.

PMID:
16608400
5.

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Review.

PMID:
22339463
6.

Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.

Lemere CA.

Prog Brain Res. 2009;175:83-93. doi: 10.1016/S0079-6123(09)17506-4. Review.

7.

Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.

Nitsch RM, Hock C.

Neurotherapeutics. 2008 Jul;5(3):415-20. doi: 10.1016/j.nurt.2008.05.013. Review.

8.

[Gene therapy for Alzheimer' s disease].

Iwata N, Ozawa K, Saido TC.

Nihon Rinsho. 2005 Mar;63(3):394-400. Review. Japanese.

PMID:
15773336

Supplemental Content

Support Center